静脉注射胺在治疗耐药双极性抑郁症中的症状调节和耐受性:一项回顾性研究
Alessandro Cuomo1, Simone Pardossi1, Giovanni Barillà1
1Division of Psychiatry, Department of Molecular and Developmental Medicine, University of Siena School of Medicine, Siena 53100, Italy.
Journal of affective disorders
|February 4, 2025
概括
胺有效地减少了治疗耐药双相情感障碍患者的抑郁症状,在四周内没有引起躁狂开关. 治疗耐受性很好,表现出内心紧张,睡眠和自杀念头的显著改善.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 对双极性抑郁症的抗抑郁药治疗存在风险,包括躁狂开关和症状恶化.
- 耐治疗双极性抑郁症 (TR-BD) 是一个重大的临床挑战,需要新的治疗方法.
- 现有治疗方法在TR-BD患者的有效性或耐受性通常是有限的.
研究的目的:
- 评估TR-BD患者静脉注射胺的疗效和安全性.
- 为了评估在治疗双极性抑郁症的胺治疗期间躁狂开关的风险.
- 检查胺对抑郁症状的特定影响,包括内心紧张,睡眠障碍和自杀念头.
主要方法:
- 连续一系列的59名被诊断患有双相I或II型精神障碍和耐治疗抑郁症的患者被纳入.
- 患者接受了输静脉胺注射,平均剂量为0.8mg/kg.
- 用蒙哥马利-阿斯伯格抑郁症评分表 (MADRS) 评估症状严重程度,持续时间为四周.
主要成果:
- 在为期四周的观察期间,没有患者经历过躁狂转换.
- 从治疗的第二周开始,观察到全球MADRS得分的统计显著下降.
- 在与内部紧张,睡眠减少和自杀念头相关的特定MADRS项目中发现了显著的改善,这些症状没有恶化.
结论:
- 静脉胺似乎是一种有效和安全的治疗选择,用于减少TR-BD患者的抑郁症状.
- 在这个队列中,胺治疗没有诱导躁狂切换,这表明这个人群中潜在的安全性是有利的.
- 在关键抑郁症状中观察到的改善突出显示了胺作为双极性抑郁症快速起作用抗抑郁药的潜力.
相关概念视频
01:26Psychosis: Goals of Pharmacotherapy
103
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
103
01:24Mania and Antimanic Drugs: Overview
118
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
118
01:30Electroconvulsive Therapy
22
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
22
01:28Drug Therapy
37
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
37
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
219
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
219
01:23Antidepressant Drugs: MAOIs and Other Agents
183
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
183